

List of Drugs for Rare Cancers in Hong Kong (by drug categories)

Definition of Rare Cancers

Incidence rate of less than 6 per 100,000 persons per year (source: Rare Cancers Europe)

Incidence rate of less than 15 per 100,000 persons per year (source: National Cancer Institute - USA)

Date Published 20.01.2023

The information in this file is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.

The content of the list is copyrighted by Rare Diseases Hong Kong (RDHK) and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial purpose, without prior written authorization and approval from RDHK. Individuals may print one hard copy for personal use, provided that content is unmodified and includes RDHK's copyright.

No.	Ingredients	Reference Indication	By BNF Therapeutic Class	Drug Formulary Category*	Source
1	ACTINOMYCIN D	Ewing's sarcoma, Wilm's tumour	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
2	ASPARAGINASE	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
3	BLEOMYCIN	Testicular tumours	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
4	CARBOPLATIN	Small cell lung cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
5	CARMUSTINE	Malignant glioma, Recurrent glioblastoma multiforme Hodgkin's disease, Multiple myeloma, Non-Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
6	CHLORAMBUCIL	Hodgkin's disease Non-Hodgkin's Lymphoma Waldenstrom's macroglobulinaemia Chronic lymphocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
7	CISPLATIN	Metastatic testicular tumours	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
8	CYCLOPHOSPHAMIDE	Acute lymphocytic leukaemia, Acute myeloid leukaemia, Advanced mycosis fungoides, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia, Ewing's sarcoma, Hodgkin's Lymphoma, Multiple myeloma, Non-Hodgkin's Lymphoma, Retinoblastoma, Small cell lung cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
9	CYTARABINE	Leukaemic meningitis	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
10	DACARBAZINE	Soft tissue sarcoma Metastatic melanoma Hodgkin's disease	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
11	DAUNORUBICIN	Acute leukaemia AIDS-related Kaposi's sarcoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
12	EPIRUBICIN	Acute leukaemia, Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
13	ETOPOSIDE	Small cell lung cancer Testicular cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
14	FLUOROURACIL	Pancreatic carcinoma Superficial basal cell carcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK

15	GEMCITABINE	Cancer, pancreatic	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
16	HYDROXYUREA	chronic myelogenous leukemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
17	IDARUBICIN	Acute myeloid leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
18	IRINOTECAN	Metastatic adenocarcinoma of pancreas <u>Acute lymphoblastic leukaemia</u>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
19	LOMUSTINE	Metastatic malignant melanoma, Lung cancer <u>Hodgkin's Lymphoma</u>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
20	MELPHALAN	Malignant melanoma, Soft tissue sarcoma Multiple myeloma Polycythemia vera	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
21	MERCAPTOPURINE	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
22	METHOTREXATE	Acute lymphoblastic leukaemia Choriocarcinoma, Trophoblastic neoplasm Burkitt's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
23	MITOMYCIN	Pancreatic, Head and neck cancer Superficial bladder tumours	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
24	PACLITAXEL	HER2-overexpressing advanced or metastatic breast cancer Metastatic adenocarcinoma of pancreas	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
25	PROCARBAZINE	Hodgkin's disease	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
26	THIOGUANINE	Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic myeloid leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
27	TRETINOIN	Acute promyelocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
28	VINBLASTINE	Advanced mycosis fungoides, Hodgkin's disease, Kaposi's sarcoma, Langerhans cell histiocytosis, Lymphocytic Lymphoma, Testicular cancer Choriocarcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
29	VINCRIStINE	Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Hodgkin's disease, Non-Hodgkin's Lymphoma, Small cell lung cancer, Wilm's tumour	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
30	THALIDOMIDE	Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK

31	OCTREOTIDE	Diarrhoea associated with carcinoid tumour, Flushing associated with carcinoid tumour, Necrolytic migratory erythema associated with glucagonoma, Severe secretory diarrhoea associated with vasoactive intestinal peptide-secreting tumour	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs Special Drugs	MIMS HK
32	DOXORUBICIN	Acute leukaemia, Advanced soft tissue sarcoma, Hodgkin's Lymphoma, Osteosarcoma, Wilm's tumour	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs, Self-financed item Without Safety Net	MIMS HK
33	ARSENIC TRIOXIDE	Acute promyelocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
34	BLINATUMOMAB	Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
35	BUSULPHAN	Chronic myeloid leukemia (CML)	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
36	CLADRIBINE	B cell chronic lymphocytic leukaemia Hairy cell leukaemia Waldenstrom's macroglobulinaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
37	CLOFARABINE	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
38	CRISANTASPASE (ASPARAGINASE ERW)	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
39	DOCETAXEL	Head and neck cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
40	ERLOTINIB	Metastatic pancreatic cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
41	FLUDARABINE	B cell chronic lymphocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
42	IFOSFAMIDE	Germ cell testicular carcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
43	IMATINIB	Accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia, Blast phase Philadelphia chromosome positive chronic myelogenous leukaemia Chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia Philadelphia chromosome-positive acute lymphoblastic leukaemia Myelodysplastic/myeloproliferative disease Gastrointestinal stromal tumour Dermatofibrosarcoma protuberans	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
44	MITOXANTRONE	Blast crisis in chronic myeloid leukaemia Non-Hodgkin's Lymphoma Acute myeloid leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
45	PEGASPARAGINASE	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
46	PEMETREXED	Malignant pleural mesothelioma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK
47	TEMOZOLOMIDE	Glioblastoma multiforme Refractory anaplastic astrocytoma Anaplastic astrocytoma, Recurrent glioblastoma multiforme	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	MIMS HK

48	ALEMTUZUMAB (LEMTRADA)	B cell chronic lymphocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
49	LANREOTIDE	Carcinoid syndrome	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
50	CETUXIMAB	Locally advanced squamous cell carcinoma of the head and neck Metastatic squamous cell carcinoma of the head and neck, Recurrent squamous cell carcinoma of the head and neck	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net	MIMS HK
51	RITUXIMAB	Refractory follicular Lymphoma, Relapsed follicular Lymphoma CD20-positive diffuse large B cell non-Hodgkin's Lymphoma Chronic lymphocytic leukaemia Advanced follicular non-Hodgkin's Lymphoma CD20-positive non-progressing low-grade non-Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs Self-financed item Without Safety Net	MIMS HK
52	IMATINIB	Gastrointestinal stromal tumour 胃腸道間質瘤	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs	HA Website
53	DASATINIB	Imatinib-resistant chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib)具抗藥性的慢性骨髓性白血病 Imatinib-resistant philadelphia or BCR/ABL positive acute lymphoblastic leukaemia (ALL) 對伊馬替尼(Imatinib)具抗藥性及伴有費城染色體的急性淋巴細胞白血病 Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病 Nilotinib-resistant chronic myeloid leukaemia (CML) 對尼洛替尼(Nilotinib)具抗藥性的慢性骨髓性白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Special Drugs Self-financed item With Safety Net (Samaritan Fund)	HA Website
54	ALECTINIB	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment) 間變性淋巴瘤激酶(ALK)呈陽性非小細胞肺癌 (一線治療) ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib ALK 陽性的晚期非小細胞肺癌 · 患者接受克唑替尼治療中惡化而對塞瑞替尼不耐受 · 或曾接受過克唑替尼治療而出現中樞神經系統轉移	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
55	AZACITIDINE	Acute myeloid leukaemia (AML) 急性骨髓性白血病 Chronic myelomonocytic leukaemia (CMML) 慢性粒單細胞白血病 Myelodysplastic syndromes (MDS) 骨髓增生異常綜合症	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
56	BENDAMUSTINE	Chronic lymphocytic leukaemia Multiple myeloma Non-Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK

57	CRIZOTINIB	ALK+ve non-small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌 ROS1-positive non-small cell lung cancer (NSCLC) ROS1 呈陽性非小細胞肺癌	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
58	NILOTINIB	Dasatinib-resistant chronic myeloid leukaemia (CML) 對達沙替尼(Dasatinib) 具抗藥性的慢性骨髓性白血病 Imatinib-resistant chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib) 具抗藥性的慢性骨髓性白血病 Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
59	PONATINIB	Acute lymphoblastic leukaemia (ALL) 急性淋巴細胞白血病 Chronic myeloid leukaemia (CML) 慢性骨髓性白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
60	RUXOLITINIB	Post-essential thrombocythaemia myelofibrosis, Post-polycythaemia vera myelofibrosis, Primary myelofibrosis	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
61	SORAFENIB	Hepatocellular carcinoma (HCC) 肝細胞癌	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
62	TEMOZOLOMIDE	Recurrent high grade glioma 復發的惡性神經膠質瘤	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
63	CLADRIBINE (MAVENCLAD)	B cell chronic lymphocytic leukaemia Hairy cell leukaemia Waldenstrom's macroglobulinaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
64	INTERFERON GAMMA	Chronic granulomatous disease, Malignant osteopetrosis	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
65	POMALIDOMIDE	Multiple myeloma (MM) 多發性骨髓瘤	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
66	RITUXIMAB	Maintenance therapy for relapsed follicular Lymphoma (RFL) 復發濾泡性淋巴瘤的維持性治療 Previously-untreated and relapsed / refractory chronic lymphocytic leukaemia (CLL) 從未治療及復發 / 難治慢性淋巴細胞白血病 CD20 positive diffuse large B-cell Lymphoma, Burkitt Lymphoma / Burkitt leukaemia 瀰漫性大型 B 細胞非何杰金氏淋巴瘤、伯基特淋巴瘤 / 伯基特白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
67	PLERIXAFOR	Multiple myeloma (MM) 多發性骨髓瘤 Non-Hodgkin's Lymphoma (NHL) 非何傑金氏淋巴瘤	NUTRITION AND BLOOD	Self-financed item With Safety Net (Samaritan Fund)	HA Website

68	ACALABRUTINIB	Relapsed / refractory chronic lymphocytic leukaemia (CLL) 復發或難治慢性淋巴細胞白血病 Mantle cell lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund) Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
69	SUNITINIB	Gastrointestinal tumour Advanced Renal Cell Carcinoma (RCC) Advanced Pancreatic Neuroendocrine Tumors (pNET)	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund) Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net	MIMS HK
70	IBRUTINIB	Relapsed or refractory mantle cell Lymphoma (MCL) 復發或難治性套細胞淋巴瘤 Chronic lymphocytic leukaemia (CLL) 慢性淋巴細胞白血病 Waldenstrom's macroglobulinemia 華氏巨球蛋白血症	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund) Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net	HA Website
71	BORTEZOMIB	Multiple myeloma Mantle cell Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net	MIMS HK
72	CARFILZOMIB	Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net	MIMS HK
73	MIDOSTAURIN	Acute myeloid leukaemia (AML) 急性骨髓性白血病 Systemic mastocytosis (SM) 全身性肥大細胞增生症	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net	HA Website
74	PAZOPANIB	Advanced soft tissue sarcoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net	MIMS HK
75	CERITINIB	ALK+ve non-small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌 For adult patients with ALK+ve advanced non-small cell lung cancer (NSCLC) previously treated with Crizotinib 曾經接受克唑替尼療程 · ALK 呈陽性晚期非小細胞肺癌的成年患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund) Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

76	OBINUTUZUMAB	<p>Follicular Lymphoma 濾泡性淋巴瘤</p> <p>In combination with Chlorambucil for treatment of previously untreated chronic lymphocytic leukaemia (CLL) in adult patients with comorbidities making them unsuitable for full-dose Fludarabine or Bendamustine based therapy 適用於與苯丁酸氮芥(Chlorambucil)併用·治療先前未曾接受過治療·且具有合併症而不適合接受全劑量含氟達拉濱(Fludarabine)或苯達莫司汀(Bendamustine)治療的慢性淋巴細胞白血病患者</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	<p>Self-financed item With Safety Net (Samaritan Fund)</p> <p>Self-financed item With Safety Net (CCF Medical Assistance Programmes)</p>	HA Website
77	LENALIDOMIDE	<p>Multiple myeloma (MM) 多發性骨髓瘤</p> <p>In combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用·用於治療曾接受最少一次先前療程的多發性骨髓瘤患者</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	<p>Self-financed item With Safety Net (Samaritan Fund)</p> <p>Self-financed item With Safety Net (CCF Medical Assistance Programmes)</p>	HA Website
78	Axitinib	Advanced renal cell carcinoma (RCC)	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
79	BEVACIZUMAB	<p>With carboplatin and paclitaxel for front-line fallopian tube / primary peritoneal cancer 與卡鉑和紫杉醇併用於晚期輸卵管癌和原發性腹膜癌的第一線治療</p> <p>Cervical cancer</p> <p>First line treatment of RAS mutant metastatic colorectal cancer in combination with chemotherapy in adult patients indicated for intensive treatment OR First line treatment of RAS wild type metastatic colorectal cancer in combination with chemotherapy in adult patients indicated for intensive treatment who are unsuitable for or intolerant to Cetuximab / Panitumumab 作為第一線治療·配合化療用於需接受強化治療的 RAS 突變型之轉移性大腸直腸癌成人患者 或 作為第一線治療·配合化療用於需接受強化治療的 RAS 野生型之轉移性大腸直腸癌成人患者·而患者不適合接受西妥昔單抗/ 帕木單抗治療或產生不耐受</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
80	BRENTUXIMAB VEDOTIN	<p>For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin Lymphoma (RR/HL): (i) following autologous stem cell transplant (ASCT), or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option 用於成人患者·治療復發或難治性 CD30+ 型何傑金氏淋巴瘤(HL)·而患者： (i) 已接受自身幹細胞移植·或 (ii) 經歷最少兩類自身幹細胞移植或多項化療的療程均屬不合適的選項</p> <p>For the treatment of adult patients with relapsed or refractory systemic anaplastic large cell Lymphoma 用於成人患者·治療復發或難治性全身間變性大型細胞淋巴瘤</p> <p>For the treatment of adult patients with CD30+ cutaneous T-cell Lymphoma (CTCL) after at least 1 prior systemic therapy 用於成人患者·治療 CD30+ 皮膚型 T 細胞淋巴瘤·且先前至少已接受一種全身性治療</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
81	DABRAFENIB	<p>For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年患者以治療 BRAF V600 突變呈陽性而不能切除的或轉移性黑色素瘤</p> <p>For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療·用於已完全切除腫瘤的 BRAF V600 突變 III 期黑色素瘤成人患者</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

82	Gemtuzumab Ozogamicin	In combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL) 與柔紅霉素及阿糖胞苷結合使用·用作治療 15 歲及以上患有原發性 CD33 型呈陽性的急性骨髓性白血病(急性早幼骨髓性白血病除外)·而之前未曾接受治療的患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
83	INOTUZUMAB OZOGAMICIN	As monotherapy for the treatment of transplant-eligible adult patients with relapsed or refractory CD22-positive B cell acute lymphoblastic leukaemia (ALL) that is either Philadelphia chromosome negative, or Philadelphia chromosome positive failing at least 1 prior TKI treatment 作為單一使用的藥物·用於治療適合移植的復發或難治性 CD22 陽性 B 細胞急性淋巴細胞白血病的成年患者·並為費城染色體陰性或費城染色體陽性而之前使用過至少一種酪氨酸激酶抑制劑(TKI)治療無效	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
84	IXAZOMIB	In combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用·用於治療曾接受最少一次先前療程的多發性骨髓瘤患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
85	LENVATINIB	For first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) 用於無法以手術切除腫瘤的肝癌病人·作第一線治療	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
86	NIVOLUMAB	As monotherapy for BRAF V600 wild-type unresectable or metastatic melanoma 適用於治療 BRAF V600 野生型不可切除或轉移性黑色素瘤之單一藥劑治療 For adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection 作為輔助性治療·用於腫瘤已擴散至淋巴結或其他部位·並已完全切除腫瘤的黑色素瘤患者 For the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy 治療接受含鉑化學治療時或之後疾病惡化的復發或轉移性頭頸部鱗狀細胞癌(SCCHN)病人	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
87	PEMBROLIZUMAB	For first-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score $\geq 50\%$) with no EGFR or ALK genomic tumor aberrations 用於PD-L1水平高(腫瘤比例評分 $\geq 50\%$)·且沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非小細胞肺癌的成年患者·作一線治療 Treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 治療局部晚期或轉移性泌尿道上皮癌·用於在接受鉑類組合化療期間或之後出現病情惡化·或於十二個月內接受過鉑類組合化療作為術前或術後治療的患者 As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and Brentuximab Vedotin (BV), or who are transplant-ineligible and have failed BV 單一治療用於成人患者·治療復發或難治性典型何傑金氏淋巴瘤(cHL)·而患者已曾接受自身幹細胞移植(ASCT)及維布妥昔單抗(BV)治療但失敗·或不合適自身幹細胞移植及曾接受維布妥昔單抗(BV)治療但失敗	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
88	TRAMETINIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年患者以治療BRAF V600突變呈陽性而不能切除的或轉移性黑色素瘤 For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療·用於已完全切除腫瘤的 BRAF V600突變 III 期黑色素瘤成人患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
89	VEMURAFENIB	As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年病人以治療 BRAF V600 突變呈陽性而不能切除的或轉移性黑色素瘤的單一療法	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

90	EVEROLIMUS (AFINITOR) (OR EQUIV)	For HR+ve HER2-ve advanced breast cancer, in combination with Exemestane, in postmenopausal women with bone-only disease after recurrence or progression following a non-steroidal aromatase inhibitor. 與依西美坦 (Exemestane) 併用 · 治療停經後的晚期荷爾蒙接受體陽性 · HER2 受體陰性骨轉移乳癌 · 患者先前已使用過非類固醇類之芳香環酶抑制劑治療無效	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
91	POLATUZUMAB VEDOTIN	Refractory diffuse large B-cell Lymphoma, Relapsed diffuse large B-cell Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
92	OLAPARIB	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response after first-line platinumbased chemotherapy (FIGO III-IV 期) 高分化晚期上皮性卵巢癌 · 輸卵管癌或原發性腹膜癌成人患者 · 有 BRCA 1/2 基因突變 (生殖細胞及 / 或體細胞突變) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療 Metastatic castration-resistant prostate cancer (mCRPC) 轉移性去勢療法無效前列腺癌	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net	HA Website
93	ABIRATERONE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌 · 並且已使用過多西紫杉醇(Docetaxel)而治療無效者 For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌 · 而基於預期對多西紫杉醇(Docetaxel) 治療不耐受 · 患者不適合接受多西紫杉醇(Docetaxel)治療	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net	HA Website
94	ENZALUTAMIDE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌 · 並且已使用過多西紫杉醇(Docetaxel)而治療無效者 For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌 · 而基於預期對多西紫杉醇(Docetaxel) 治療不耐受 · 患者不適合接受多西紫杉醇(Docetaxel)治療	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net	HA Website
95	ATEZOLIZUMAB	For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. 適用於治療未曾接受全身系統性療程且晚期或無法切除的肝細胞癌(HCC)成年患者 For EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinumbased chemotherapy 用於患有 EGFR 基因變異陰性及 ALK-陰性轉移性非小細胞肺癌(NSCLC) 並曾接受含鉑化療而病情惡化的患者 As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression \geq 50% tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC 作為單一藥物治療 · 用於沒有 EGFR 基因變異或 ALK呈陽性的轉移性非小細胞肺癌 (NSCLC) 的成年患者之第一線治療 · 其腫瘤的 PD-L1 基因表達程度 \geq 50%	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net	HA Website

96	DOXORUBICIN (LIPOSOMAL)	Ovarian cancer Acute leukaemia, Advanced soft tissue sarcoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Osteosarcoma, Wilm's tumour AIDS-related Kaposi's sarcoma Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net	MIMS HK
97	ACALABRUTINIB	Chronic lymphocytic leukemia (CLL) in adults.	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
98	BENDAMUSTINE	Chronic lymphocytic leukaemia Multiple myeloma Non-Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
99	BRENTUXIMAB VEDOTIN	Hodgkin's disease Anaplastic large cell Lymphoma CD-30 positive cutaneous T-cell Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
100	CABOZANTINIB (CABOMETYX)	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated w/ sorafenib.	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
101	DARATUMUMAB	Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
102	DOCETAXEL	Head and neck cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
103	LENVATINIB	Unresectable hepatocellular carcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
104	NIRAPARIB (TOSYLATE)	Fallopian tube, primary peritoneal cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
105	NIRAPARIB (ZEJULA)	Ovarian cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	HA Website
106	NIVOLUMAB	Locally advanced squamous cell carcinoma of the head and neck, Metastatic squamous cell carcinoma of the head and neck, Metastatic urothelial carcinoma, Refractory classical Hodgkin Lymphoma, Relapsed classical Hodgkin Lymphoma Hepatocellular carcinoma Metastatic melanoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
107	OBINUTUZUMAB	Follicular Lymphoma Chronic lymphocytic leukaemia Refractory follicular Lymphoma, Relapsed follicular Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
108	PACLITAXEL (ALBUMIN)	HER2-overexpressing advanced or metastatic breast cancer Metastatic adenocarcinoma of pancreas AIDS-related Kaposi's sarcoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK

109	PEMBROLIZUMAB	<p>PD-L1 expression in metastatic gastroesophageal junction adenocarcinoma, PD-L1 expression in recurrent locally advanced gastroesophageal junction adenocarcinoma</p> <p>PD-L1 expression in metastatic cervical cancer, PD-L1 expression in recurrent cervical cancer</p> <p>PD-L1 expression in metastatic squamous cell carcinoma of the head and neck, PD-L1 expression in unresectable recurrent squamous cell carcinoma of the head and neck</p> <p>Metastatic melanoma</p> <p>Metastatic squamous cell carcinoma of the head and neck, Recurrent squamous cell carcinoma of the head and neck</p> <p>Refractory classical Hodgkin Lymphoma, Relapsed classical Hodgkin Lymphoma</p> <p>Primary mediastinal large B-cell Lymphoma</p> <p>Metastatic urothelial carcinoma</p> <p>Metastatic microsatellite instability-high colorectal cancer</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
110	REGORAFENIB	Unresectable, metastatic malignant gastrointestinal stromal tumours	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
111	TOPOTECAN	<p>Small cell lung cancer</p> <p>Cervical cancer</p> <p>Small cell lung cancer</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
112	VENETOCLAX	<p>Chronic lymphocytic leukaemia, Small lymphocytic Lymphoma</p> <p>Acute myeloid leukaemia</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
113	LENALIDOMIDE	<p>Multiple myeloma</p> <p>Myelodysplastic syndrome</p> <p>Mantle cell Lymphoma</p> <p>Follicular Lymphoma, Marginal zone Lymphoma</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
114	LORLATINIB	Metastatic non-small cell lung carcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK

Hospital Authority "Drug Formulary" categories*

General Drugs

These are drugs with well-established indications and cost- effectiveness which are available for general use as indicated by patients with relevant clinical conditions and provided at standard fees and charges in public hospitals and clinics.

Special Drugs

These are drugs used under specific clinical conditions with specific specialist authorisation. Special drugs are provided at standard fees and charges in public hospitals and clinics when prescribed under specific clinical conditions. Patients who do not meet the specified clinical conditions but choose to use Special drugs are required to pay for the drugs.

Self-financed Items (SFIs) with Safety Net

These are drugs which are proven to be of significant clinical benefits but are very expensive for HA to provide as part of its standard services. These drugs are not covered by the standard fees and charges in public hospitals and clinics. Patients who require these drugs and can afford the costs have to purchase the drugs at their own expense. A safety net is provided through relevant funds to subsidize the drug expenses of patients who have financial difficulties.

SFIs without Safety Net

These include drugs with preliminary medical evidence only, drugs with marginal benefits over available alternatives but at significant higher costs, and lifestyle drugs (e.g. anti-obesity drugs). These drugs are not provided as part of HA's standard services nor covered by the standard fees and charges in public hospitals and clinics. Patients who choose to use these drugs must purchase them at their own expense.

*Reference: HA Drug Formulary Website

List of Drugs for Rare Cancers in Hong Kong (by cancer types)

Definition of Rare Cancers

Incidence rate of less than 6 per 100,000 persons per year (source: Rare Cancers Europe)

Incidence rate of less than 15 per 100,000 persons per year (source: National Cancer Institute - USA)

Date Published 20.01.2023

The information in this file is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.

The content of the list is copyrighted by Rare Diseases Hong Kong (RDHK) and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial purpose, without prior written authorization and approval from RDHK. Individuals may print one hard copy for personal use, provided that content is unmodified and includes RDHK's copyright.

No.	Ingredients	Indications	Cancer Types	Drug Categories*	Sources of drug information
1	MITOMYCIN	Superficial bladder tumours	Bladder cancer	General Drugs	MIMS HK
2	NIVOLUMAB	Metastatic urothelial carcinoma	Bladder cancer	Self-financed item Without Safety Net	MIMS HK
3	PEMBROLIZUMAB	Metastatic urothelial carcinoma	Bladder cancer	Self-financed item Without Safety Net	MIMS HK
4	BRENTUXIMAB VEDOTIN	For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin Lymphoma (RR/HL): (i) following autologous stem cell transplant (ASCT), or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option 用於成人患者，治療復發或難治性 CD30+型何傑金氏淋巴瘤(HL)，而患者： (i) 已接受自身幹細胞移植，或 (ii) 經歷最少兩類自身幹細胞移植或多項化療的療程均屬不合適的選項	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
5	BRENTUXIMAB VEDOTIN	For the treatment of adult patients with relapsed or refractory systemic anaplastic large cell Lymphoma 用於成人患者，治療復發或難治性全身間變性大型細胞淋巴瘤	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
6	BRENTUXIMAB VEDOTIN	For the treatment of adult patients with CD30+ cutaneous T-cell Lymphoma (CTCL) after at least 1 prior systemic therapy 用於成人患者，治療 CD30+皮膚型 T 細胞淋巴瘤，且先前至少已接受一種全身性治療	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
7	Gemtuzumab Ozogamicin	In combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive Acute myeloid leukaemia (AML), except Acute promyelocytic leukaemia (APL) 與柔紅霉素及阿糖胞苷結合使用，用作治療 15 歲及以上患有原發性 CD33 型呈陽性的急性骨髓性白血病(急性早幼骨髓性白血病除外)，而之前未曾接受治療的患者	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
8	INOTUZUMAB OZOGAMICIN	As monotherapy for the treatment of transplant-eligible adult patients with relapsed or refractory CD22-positive B cell Acute lymphoblastic leukaemia (ALL) that is either Philadelphia chromosome negative, or Philadelphia chromosome positive failing at least 1 prior TKI treatment 作為單一使用的藥物，用於治療適合移植的復發或難治性 CD22 陽性 B 細胞急性淋巴細胞白血病的成年患者，並為費城染色體陰性或費城染色體陽性而之前使用過至少一種酪氨酸激酶抑制劑(TKI)治療無效	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
9	ACALABRUTINIB	Relapsed / refractory Chronic lymphocytic leukaemia (CLL) 復發或難治慢性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
10	AZACITIDINE	Acute myeloid leukaemia (AML) 急性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
11	AZACITIDINE	Chronic myelomonocytic leukaemia (CMML) 慢性粒單細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
12	AZACITIDINE	Myelodysplastic syndromes (MDS) 骨髓增生異常綜合症	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
13	BENDAMUSTINE	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
14	BORTEZOMIB	Mantle cell Lymphoma	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
15	DASATINIB	Imatinib-resistant Chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website

16	DASATINIB	Imatinib-resistant philadelphia or BCR/ABL positive Acute lymphoblastic leukaemia (ALL) 對伊馬替尼(Imatinib)具抗藥性及伴有費城染色體的急性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
17	DASATINIB	Newly diagnosed Chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
18	DASATINIB	Nilotinib-resistant Chronic myeloid leukaemia (CML) 對尼洛替尼(Nilotinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
19	IBRUTINIB	Relapsed or refractory mantle cell Lymphoma (MCL) 復發或難治性套細胞淋巴瘤	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
20	IBRUTINIB	Chronic lymphocytic leukaemia (CLL) 慢性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
21	IBRUTINIB	Waldenstrom's macroglobulinemia 華氏巨球蛋白血症	Blood and bone marrow cancer	Self-financed item Without Safety Net	HA Website
22	MIDOSTAURIN	Acute myeloid leukaemia (AML) 急性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
23	MIDOSTAURIN	Systemic mastocytosis (SM) 全身性肥大細胞增生症	Blood and bone marrow cancer	Self-financed item Without Safety Net	HA Website
24	NILOTINIB	Dasatinib-resistant Chronic myeloid leukaemia (CML) 對達沙替尼(Dasatinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
25	NILOTINIB	Imatinib-resistant Chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
26	NILOTINIB	Newly diagnosed Chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
27	PONATINIB	Acute lymphoblastic leukaemia (ALL) 急性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
28	PONATINIB	Chronic myeloid leukaemia (CML) 慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
29	RUXOLITINIB	Post-essential thrombocythaemia myelofibrosis	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
30	RUXOLITINIB	Post-polycythaemia vera myelofibrosis	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
31	RUXOLITINIB	Primary myelofibrosis	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
32	RUXOLITINIB	Polycythemia vera	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
33	CLADRIBINE (MAVENCLAD)	B cell Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
34	CLADRIBINE (MAVENCLAD)	Hairy cell leukaemia	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
35	RITUXIMAB	Maintenance therapy for relapsed follicular Lymphoma (RFL) 復發濾泡性淋巴瘤的維持性治療	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
36	RITUXIMAB	Previously-untreated and relapsed / refractory Chronic lymphocytic leukaemia (CLL) 從未治療及復發 / 難治慢性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
37	RITUXIMAB	CD20 positive diffuse large B-cell Lymphoma 瀰漫性大型 B 細胞非何杰金氏淋巴瘤	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
38	RITUXIMAB	CD20 positive diffuse Burkitt Lymphoma 瀰漫性伯基特淋巴瘤	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
39	RITUXIMAB	CD20 positive diffuse Burkitt leukaemia 瀰漫性伯基特白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website

40	OBINUTUZUMAB	In combination with Chlorambucil for treatment of previously untreated Chronic lymphocytic leukaemia (CLL) in adult patients with comorbidities making them unsuitable for full-dose Fludarabine or Bendamustine based therapy 適用於與苯丁酸氮芥(Chlorambucil)併用，治療先前未曾接受過治療，且具有合併症而不適合接受全劑量含氟達拉濱(Fludarabine)或苯達莫司汀(Bendamustine)治療的慢性淋巴細胞白血病患者	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
41	ASPARAGINASE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
42	CHLORAMBUCIL	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
43	CYCLOPHOSPHAMIDE	Acute lymphocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
44	CYCLOPHOSPHAMIDE	Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
45	CYCLOPHOSPHAMIDE	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
46	CYCLOPHOSPHAMIDE	Chronic myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
47	CYTARABINE	Leukaemic meningitis	Blood and bone marrow cancer	General Drugs	MIMS HK
48	DAUNORUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
49	DOXORUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
50	EPIRUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
51	HYDROXYUREA	chronic myelogenous leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
52	IDARUBICIN	Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
53	IDARUBICIN	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
54	MELPHALAN	Polycythemia vera	Blood and bone marrow cancer	General Drugs	MIMS HK
55	MERCAPTOPURINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
56	METHOTREXATE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
57	THIOGUANINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
58	THIOGUANINE	Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
59	THIOGUANINE	Chronic myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
60	TRETINOIN	Acute promyelocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
61	VINCRISTINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
62	VINCRISTINE	Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
63	ARSENIC TRIOXIDE	Acute promyelocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
64	BLINATUMOMAB	Philadelphia chromosome-negative precursor B-cell Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
65	BUSULPHAN	Chronic myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
66	CLADRIBINE	B cell Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
67	CLADRIBINE	Hairy cell leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
68	CLOFARABINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
69	CRISANTASPASE (ASPARAGINASE ERW)	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
70	DASATINIB	Chronic myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
71	FLUDARABINE	B cell Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
72	IMATINIB	Accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
73	IMATINIB	Blast phase Philadelphia chromosome positive chronic myelogenous leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
74	IMATINIB	Chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
75	IMATINIB	Philadelphia chromosome-positive Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
76	IMATINIB	Myelodysplastic/myeloproliferative disease	Blood and bone marrow cancer	Special Drugs	MIMS HK
77	MITOXANTRONE	Blast crisis in Chronic myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
78	MITOXANTRONE	Acute myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
79	PEGASPARAGINASE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
80	ALEMTUZUMAB (LEMTRADA)	B cell Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK

81	RITUXIMAB	Refractory follicular Lymphoma	Blood and bone marrow cancer	Special Drugs	MIMS HK
82	RITUXIMAB	Relapsed follicular Lymphoma	Blood and bone marrow cancer	Special Drugs	MIMS HK
83	RITUXIMAB	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
84	BENDAMUSTINE	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
85	DOXORUBICIN (LIPOSOMAL)	Acute leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
86	OBINUTUZUMAB	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
87	VENETOCLAX	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
88	VENETOCLAX	Small lymphocytic Lymphoma	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
89	VENETOCLAX	Acute myeloid leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
90	LENALIDOMIDE	Myelodysplastic syndrome	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
91	RITUXIMAB	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
92	CYCLOPHOSPHAMIDE	Advanced mycosis fungoides	Blood cancer	General Drugs	MIMS HK
93	VINBLASTINE	Advanced mycosis fungoides	Blood cancer	General Drugs	MIMS HK
94	DOXORUBICIN	Osteosarcoma	Bone cancer	General Drugs	MIMS HK
95	DOXORUBICIN (LIPOSOMAL)	Osteosarcoma	Bone cancer	Self-financed item Without Safety Net	MIMS HK
96	IXAZOMIB	In combination with dexamethasone for the treatment of Multiple myeloma in patients who have received at least one prior therapy	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
97	LENALIDOMIDE	Multiple myeloma (MM) 多發性骨髓瘤	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
98	LENALIDOMIDE	In combination with dexamethasone for the treatment of Multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用，用於治療曾接受最少一次先前療程的多發性骨髓瘤患者	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
99	BENDAMUSTINE	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
100	BORTEZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
101	POMALIDOMIDE	Multiple myeloma (MM) 多發性骨髓瘤	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
102	Plerixafor	Multiple myeloma (MM) 多發性骨髓瘤	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
103	CARMUSTINE	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
104	CYCLOPHOSPHAMIDE	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
105	EPIRUBICIN	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
106	MELPHALAN	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
107	THALIDOMIDE	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
108	CARFILZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net	MIMS HK
109	BENDAMUSTINE	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
110	BORTEZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
111	CARFILZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
112	DARATUMUMAB	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
113	DOXORUBICIN (LIPOSOMAL)	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
114	LENALIDOMIDE	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
115	ACTINOMYCIN D	Ewing's sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
116	CYCLOPHOSPHAMIDE	Ewing's sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
117	DACARBAZINE	Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
118	DOXORUBICIN	Advanced Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
119	MELPHALAN	Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK

120	DOXORUBICIN (LIPOSOMAL)	Advanced Soft tissue sarcoma	Bone or soft tissue cancer	Self-financed item Without Safety Net	MIMS HK
121	PAZOPANIB	Advanced Soft tissue sarcoma	Bone or soft tissue cancer	Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net	MIMS HK
122	CARMUSTINE	Malignant glioma	Brain and spinal cord cancer	General Drugs	MIMS HK
123	TEMOZOLOMIDE	Recurrent high grade glioma 復發的惡性神經膠質瘤	Brain cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
124	CARMUSTINE	Recurrent glioblastoma multiforme	Brain cancer	General Drugs	MIMS HK
125	TEMOZOLOMIDE	Glioblastoma multiforme	Brain cancer	Special Drugs	MIMS HK
126	TEMOZOLOMIDE	Refractory anaplastic astrocytoma	Brain cancer	Special Drugs	MIMS HK
127	TEMOZOLOMIDE	Anaplastic astrocytoma	Brain cancer	Special Drugs	MIMS HK
128	TEMOZOLOMIDE	Recurrent glioblastoma multiforme	Brain cancer	Special Drugs	MIMS HK
129	BEVACIZUMAB	Glioblastoma	Brain cancer	Self-financed item Without Safety Net	MIMS HK
130	PACLITAXEL	HER2-overexpressing advanced or metastatic breast cancer	Breast cancer	General Drugs	MIMS HK
131	PACLITAXEL (ALBUMIN)	HER2-overexpressing advanced or metastatic breast cancer	Breast cancer	Self-financed item Without Safety Net	MIMS HK
132	BEVACIZUMAB	Cervical cancer	Cervical cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
133	PEMBROLIZUMAB	PD-L1 expression in metastatic cervical cancer	Cervical cancer	Self-financed item Without Safety Net	MIMS HK
134	PEMBROLIZUMAB	PD-L1 expression in recurrent cervical cancer	Cervical cancer	Self-financed item Without Safety Net	MIMS HK
135	TOPOTECAN	Cervical cancer	Cervical cancer	Self-financed item Without Safety Net	MIMS HK
136	PEMBROLIZUMAB	Metastatic microsatellite instability-high colorectal cancer	Colorectal cancer	Self-financed item Without Safety Net	MIMS HK
137	BEVACIZUMAB	First line treatment of RAS mutant metastatic colorectal cancer in combination with chemotherapy in adult patients indicated for intensive treatment OR First line treatment of RAS wild type metastatic colorectal cancer in combination with chemotherapy in adult patients indicated for intensive treatment who are unsuitable for or intolerant to Cetuximab / Panitumumab 作為第一線治療·配合化療用於需接受強化治療的 RAS突變型之轉移性大腸直腸癌成人患者 或 作為第一線治療·配合化療用於需接受強化治療的 RAS 野生型之轉移性大腸直腸癌成人患者·而患者不適合接受西妥昔單抗/帕木單抗治療或產生不耐受	Colorectal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
138	DAUNORUBICIN	AIDS-related Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
139	PACLITAXEL	AIDS-related Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
140	VINBLASTINE	Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
141	DOXORUBICIN (LIPOSOMAL)	AIDS-related Kaposi's sarcoma	Endothelial cell cancer	Self-financed item Without Safety Net	MIMS HK
142	PACLITAXEL (ALBUMIN)	AIDS-related Kaposi's sarcoma	Endothelial cell cancer	Self-financed item Without Safety Net	MIMS HK
143	BEVACIZUMAB	With carboplatin and paclitaxel for front-line fallopian tube [fallopian tube cancers] / primary peritoneal cancer 與卡铂和紫杉醇併用於晚期輸卵管癌和原發性腹膜癌的第一線治療	Epithelial ovarian / fallopian tube / primary peritoneal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
144	PEMBROLIZUMAB	PD-L1 expression in metastatic gastroesophageal junction adenocarcinoma	Esophagus cancer	Self-financed item Without Safety Net	MIMS HK
145	PEMBROLIZUMAB	PD-L1 expression in recurrent locally advanced gastroesophageal junction adenocarcinoma	Esophagus cancer	Self-financed item Without Safety Net	MIMS HK
146	CYCLOPHOSPHAMIDE	Retinoblastoma	Eye cancer	General Drugs	MIMS HK
147	OLAPARIB	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade fallopian tube cancer who are in complete or partial response after first-line platinum based chemotherapy (FIGO III-IV 期) 高分化晚期上輸卵管癌患者·有 BRCA 1/2 基因突變 (生殖細胞及 / 或體細胞突變) 而完成一線鉑類化療後有完全或部分緩解的維持治療	Fallopian tube cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
148	NIRAPARIB (TOSYLATE)	Fallopian tube cancer	Fallopian tube cancer	Self-financed item Without Safety Net	MIMS HK
149	SUNITINIB	Gastrointestinal tumour 腸胃癌	Gastrointestinal cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website

150	IMATINIB	Gastrointestinal stromal tumour 胃腸道間質瘤	Gastrointestinal cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
151	EVEROLIMUS (AFINITOR) (OR EQUIV)	Neuroendocrine tumours of gastrointestinal origin	Gastrointestinal cancer	Special Drugs	MIMS HK
152	IMATINIB	Gastrointestinal stromal tumour	Gastrointestinal cancer	Special Drugs	MIMS HK
153	REGORAFENIB	Unresectable, metastatic malignant gastrointestinal stromal tumours	Gastrointestinal cancer	Self-financed item Without Safety Net	MIMS HK
154	BLEOMYCIN	Testicular tumours	Germ cell tumor	General Drugs	MIMS HK
155	CISPLATIN	Metastatic Testicular tumours	Germ cell tumor	General Drugs	MIMS HK
156	ETOPOSIDE	Testicular cancer	Germ cell tumor	General Drugs	MIMS HK
157	VINBLASTINE	Testicular cancer	Germ cell tumor	General Drugs	MIMS HK
158	METHOTREXATE	Trophoblastic neoplasm	Gestational trophoblastic cancer	General Drugs	MIMS HK
159	MITOMYCIN	Head and neck cancer	Head and neck cancer	General Drugs	MIMS HK
160	DOCETAXEL	Head and neck cancer	Head and neck cancer	Special Drugs	MIMS HK
161	DOCETAXEL	Head and neck cancer	Head and neck cancer	Self-financed item Without Safety Net	MIMS HK
162	VINBLASTINE	Langerhans cell histiocytosis	Histiocytes cancer	General Drugs	MIMS HK
163	Axitinib	Advanced renal cell carcinoma (RCC)	Kidney cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
164	ACTINOMYCIN D	Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
165	DOXORUBICIN	Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
166	VINCRISTINE	Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
167	DOXORUBICIN (LIPOSOMAL)	Wilm's tumour	Kidney cancer	Self-financed item Without Safety Net	MIMS HK
168	SUNITINIB	Advanced Renal Cell Carcinoma (RCC)	Kidney cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
169	ATEZOLIZUMAB	For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. 適用於治療未曾接受全身系統性療程且晚期或無法切除的肝細胞癌(HCC)成年患者	Liver cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
170	LENVATINIB	For first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) 用於無法以手術切除腫瘤的肝癌病人·作第一線治療	Liver cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
171	SORAFENIB	Hepatocellular carcinoma (HCC) 肝細胞癌	Liver cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
172	CABOZANTINIB (CABOMETYX)	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated w/ sorafenib	Liver cancer	Self-financed item Without Safety Net	MIMS HK
173	LENVATINIB	Unresectable hepatocellular carcinoma	Liver cancer	Self-financed item Without Safety Net	MIMS HK
174	NIVOLUMAB	Hepatocellular carcinoma	Liver cancer	Self-financed item Without Safety Net	MIMS HK
175	ATEZOLIZUMAB	For EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinumbased chemotherapy 用於患有 EGFR 基因變異陰性及 ALK-陰性轉移性非小細胞肺癌(NSCLC) 並曾接受含鉑化療而病情惡化的患者 As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression >=50% tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC 作為單一藥物治療·用於沒有 EGFR 基因變異或 ALK呈陽性的轉移性非小細胞肺癌 (NSCLC) 的成年患者之第一線治療·其腫瘤的 PD-L1 基因表達程度 ≥50%	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
176	PEMBROLIZUMAB	For first-line treatment for metastatic non-Small cell lung cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score >=50%) with no EGFR or ALK genomic tumor aberrations 用於 PD-L1 水平高 (腫瘤比例評分 ≥ 50%) · 且沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK) 基因突變的轉移性非小細胞肺癌的成年患者·作一線治療	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
177	ALECTINIB	ALK+ve non-Small cell lung cancer (NSCLC) (first-line treatment) 間變性淋巴瘤激酶(ALK)呈陽性非小細胞肺癌 (一線治療)	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website

178	ALECTINIB	ALK+ve metastatic non-Small cell lung cancer] (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib~ ALK 陽性的晚期非小細胞肺癌。患者接受克唑替尼治療中惡化而對塞瑞替尼不耐受。或曾接受過克唑替尼治療而出現中樞神經系統轉移~	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
179	CRIZOTINIB	ALK+ve non-Small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
180	CRIZOTINIB	ROS1-positive non-Small cell lung cancer (NSCLC) ROS1 呈陽性非小細胞肺癌	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
181	CERITINIB	ALK+ve non-Small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌	Lung cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
182	CERITINIB	For adult patients with ALK+ve advanced non-Small cell lung cancer (NSCLC) previously treated with Crizotinib 曾經接受克唑替尼療程。ALK 呈陽性晚期非小細胞肺癌的成年患者	Lung cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
183	CARBOPLATIN	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
184	CYCLOPHOSPHAMIDE	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
185	ETOPOSIDE	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
186	LOMUSTINE	Lung cancer	Lung cancer	General Drugs	MIMS HK
187	VINCRIStINE	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
188	EVEROLIMUS (AFINITOR) (OR EQUIV)	Neuroendocrine tumours of lung origin	Lung cancer	Special Drugs	MIMS HK
189	PEMETREXED	Malignant pleural mesothelioma	Lung cancer	Special Drugs	MIMS HK
190	TOPOTECAN	Small cell lung cancer	Lung cancer	Self-financed item Without Safety Net	MIMS HK
191	TOPOTECAN	Small cell lung cancer	Lung cancer	Self-financed item Without Safety Net	MIMS HK
192	LORLATINIB	Metastatic non-small cell lung carcinoma	Lung cancer	Self-financed item Without Safety Net	MIMS HK
193	PEMBROLIZUMAB	As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and Brentuximab Vedotin (BV), or who are transplant-ineligible and have failed BV 單一治療用於成人患者。治療復發或難治性典型何傑金氏淋巴瘤(cHL)。而患者已曾接受自身幹細胞移植(ASCT)及維布妥昔單抗(BV)治療但失敗。或不合適自身幹細胞移植及曾接受維布妥昔單抗(BV)治療但失敗^	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
194	BENDAMUSTINE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
195	CLADRIBINE (MAVENCLAD)	Waldenstrom's macroglobulinaemia	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
196	Plerixafor	Non-Hodgkin's Lymphoma (NHL) 非何傑金氏淋巴瘤	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
197	OBINUTUZUMAB	Follicular Lymphoma 濾泡性淋巴瘤	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
198	CARMUSTINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
199	CARMUSTINE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
200	CHLORAMBUCIL	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
201	CHLORAMBUCIL	Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
202	CHLORAMBUCIL	Waldenstrom's macroglobulinaemia	Lymphatic system cancer	General Drugs	MIMS HK
203	CYCLOPHOSPHAMIDE	Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
204	CYCLOPHOSPHAMIDE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
205	DACARBAZINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK

206	DOXORUBICIN	Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
207	LOMUSTINE	Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
208	METHOTREXATE	Burkitt's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
209	PROCARBAZINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
210	VINBLASTINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
211	VINBLASTINE	Lymphocytic Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
212	VINCRISTINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
213	VINCRISTINE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
214	CLADRIBINE	Waldenstrom's macroglobulinaemia	Lymphatic system cancer	Special Drugs	MIMS HK
215	MITOXANTRONE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK
216	RITUXIMAB	CD20-positive diffuse large B cell Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK
217	RITUXIMAB	Advanced follicular Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK
218	RITUXIMAB	CD20-positive non-progressing low-grade Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK
219	ACALABRUTINIB	Mantle cell Lymphoma (MCL)	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
220	ACALABRUTINIB	Chronic lymphocytic leukaemia (CLL) in adults	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
221	BENDAMUSTINE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
222	BORTEZOMIB	Mantle cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
223	BRENTUXIMAB VEDOTIN	Hodgkin's disease	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
224	BRENTUXIMAB VEDOTIN	Anaplastic large cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
225	BRENTUXIMAB VEDOTIN	CD-30 positive cutaneous T-cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
226	DOXORUBICIN (LIPOSOMAL)	Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
227	DOXORUBICIN (LIPOSOMAL)	Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
228	NIVOLUMAB	Refractory classical Hodgkin Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
229	NIVOLUMAB	Relapsed classical Hodgkin Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
230	OBINUTUZUMAB	Follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
231	OBINUTUZUMAB	Refractory follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
232	OBINUTUZUMAB	Relapsed follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
233	PEMBROLIZUMAB	Refractory classical Hodgkin Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
234	PEMBROLIZUMAB	Relapsed classical Hodgkin Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
235	PEMBROLIZUMAB	Primary mediastinal large B-cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
236	POLATUZUMAB VEDOTIN	Refractory diffuse large B-cell Lymphoma	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
237	POLATUZUMAB VEDOTIN	Relapsed diffuse large B-cell Lymphoma	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
238	LENALIDOMIDE	Mantle cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
239	LENALIDOMIDE	Follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
240	LENALIDOMIDE	Marginal zone Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
241	RITUXIMAB	Refractory follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
242	RITUXIMAB	Relapsed follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
243	RITUXIMAB	CD20-positive diffuse large B cell Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
244	RITUXIMAB	Advanced follicular Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
245	RITUXIMAB	CD20-positive non-progressing low-grade Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
246	OCTREOTIDE	Severe secretory diarrhoea associated with vasoactive intestinal peptide-secreting tumour	Neuroendocrine cancer	General Drugs	MIMS HK
247	OCTREOTIDE	Diarrhoea associated with carcinoid tumour	Neuroendocrine cancer	General Drugs	MIMS HK
248	OCTREOTIDE	Flushing associated with carcinoid tumour	Neuroendocrine cancer	General Drugs	MIMS HK

249	LANREOTIDE	Carcinoid syndrome	Neuroendocrine cancer	Special Drugs	MIMS HK
250	OLAPARIB	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian cancer who are in complete or partial response after first-line platinum based chemotherapy. (FIGO III-IV 期) 高分化晚期上皮性卵巢癌患者 · 有 BRCA 1/2 基因突變 (生殖細胞及 / 或體細胞突變) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療	Ovarian cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
251	NIRAPARIB	Ovarian cancer	Ovarian cancer	Self-financed item Without Safety Net	HA Website
252	DOXORUBICIN (LIPOSOMAL)	Second-line of platinum refractory or subsequent treatment of platinum resistant advanced ovarian cancer 鉑化合物無效後的第二線或後續鉑化合物抗藥的卵巢癌治療	Ovarian cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
253	FLUOROURACIL	Pancreatic carcinoma	Pancreatic cancer	General Drugs	MIMS HK
254	GEMCITABINE	Pancreatic Cancer	Pancreatic cancer	General Drugs	MIMS HK
255	IRINOTECAN	Metastatic adenocarcinoma of pancreas	Pancreatic cancer	General Drugs	MIMS HK
256	MITOMYCIN	Pancreatic cancer	Pancreatic cancer	General Drugs	MIMS HK
257	PACLITAXEL	Metastatic adenocarcinoma of pancreas	Pancreatic cancer	General Drugs	MIMS HK
258	OCTREOTIDE	Necrolytic migratory erythema associated with glucagonoma	Pancreatic cancer	General Drugs	MIMS HK
259	ERLOTINIB	Metastatic pancreatic cancer	Pancreatic cancer	Special Drugs	MIMS HK
260	EVEROLIMUS (AFINITOR) (OR EQUIV)	Neuroendocrine tumours of pancreatic origin	Pancreatic cancer	Special Drugs	MIMS HK
261	EVEROLIMUS (AFINITOR) (OR EQUIV)	Unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults w/ progressive disease	Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
262	PACLITAXEL (ALBUMIN)	Metastatic adenocarcinoma of pancreas	Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
263	SUNITINIB	Advanced Pancreatic Neuroendocrine Tumors (pNET)	Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
264	OLAPARIB	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade primary peritoneal cancer who are in complete or partial response after first-line platinum based chemotherapy (FIGO III-IV 期) 高分化晚期上原發性腹膜癌成人患者 · 有 BRCA 1/2 基因突變 (生殖細胞及 / 或體細胞突變) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療	Peritoneal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
265	NIRAPARIB (TOSYLATE)	primary peritoneal cancer	Peritoneal cancer	Self-financed item Without Safety Net	MIMS HK
266	ABIRATERONE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌 · 並且已使用過多西紫杉醇(Docetaxel)而治療無效者	Prostate cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
267	ABIRATERONE	For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌 · 而基於預期對多西紫杉醇(Docetaxel)治療不耐受 · 患者不適合接受多西紫杉醇(Docetaxel)治療	Prostate cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
268	ENZALUTAMIDE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌 · 並且已使用過多西紫杉醇(Docetaxel)而治療無效者	Prostate cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
269	ENZALUTAMIDE	For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌 · 而基於預期對多西紫杉醇(Docetaxel)治療不耐受 · 患者不適合接受多西紫杉醇(Docetaxel)治療	Prostate cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
270	OLAPARIB	Metastatic castration-resistant prostate cancer (mCRPC) 轉移性去勢療法無效前列腺癌	Prostate cancer	Self-financed item Without Safety Net	HA Website
271	DABRAFENIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or Metastatic melanoma 用於成年患者以治療BRAF V600突變呈陽性而不能切除的或轉移性黑色素瘤	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
272	DABRAFENIB	For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療 · 用於已完全切除腫瘤的 BRAF V600突變 III 期黑色素瘤成人患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

273	NIVOLUMAB	As monotherapy for BRAF V600 wild-type unresectable or Metastatic melanoma 適用於治療 BRAF V600 野生型不可切除或轉移性黑色素瘤之單一藥劑治療	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
274	NIVOLUMAB	For adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection 作為輔助性治療·用於腫瘤已擴散至淋巴結或其他部位·並已完全切除腫瘤的黑色素瘤患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
275	NIVOLUMAB	For the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy 治療接受含鉑化學治療時或之後疾病惡化的復發或轉移性頭頸部鱗狀細胞癌(SCCHN)病人	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
276	TRAMETINIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or Metastatic melanoma 用於成年患者以治療BRAF V600突變呈陽性而不能切除的或轉移性黑色素瘤	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
277	TRAMETINIB	For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療·用於已完全切除腫瘤的 BRAF V600突變 III 期黑色素瘤成人患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
278	VEMURAFENIB	As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or Metastatic melanoma 用於成年病人以治療 BRAF V600 突變呈陽性而不能切除的或轉移性黑色素瘤的單一療法	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
279	PEMBROLIZUMAB	Treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 治療局部晚期或轉移性泌尿道上皮癌·用於在接受鉑類組合化療期間或之後出現病情惡化·或於十二個月內接受過鉑類組合化療作為術前或術後治療的患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
280	CETUXIMAB	Locally advanced squamous cell carcinoma of the head and neck	skin cancer	Special Drugs	MIMS HK
281	CETUXIMAB	Metastatic squamous cell carcinoma of the head and neck	skin cancer	Special Drugs	MIMS HK
282	CETUXIMAB	Recurrent squamous cell carcinoma of the head and neck	skin cancer	Special Drugs	MIMS HK
283	DACARBAZINE	Metastatic melanoma	Skin cancer	General Drugs	MIMS HK
284	LOMUSTINE	Metastatic malignant melanoma	Skin cancer	General Drugs	MIMS HK
285	MELPHALAN	Malignant melanoma	Skin cancer	General Drugs	MIMS HK
286	IMATINIB	Dermatofibrosarcoma protuberans	Skin cancer	Special Drugs	MIMS HK
287	CETUXIMAB	Locally advanced squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
288	CETUXIMAB	Metastatic squamous cell carcinoma of the head and neck / Recurrent squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
289	NIVOLUMAB	Locally advanced squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
290	NIVOLUMAB	Metastatic squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
291	NIVOLUMAB	Metastatic melanoma	Skin cancer	Self-financed item Without Safety Net	MIMS HK
292	PEMBROLIZUMAB	PD-L1 expression in metastatic squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
293	PEMBROLIZUMAB	PD-L1 expression in unresectable recurrent squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
294	PEMBROLIZUMAB	Metastatic melanoma	Skin cancer	Self-financed item Without Safety Net	MIMS HK
295	PEMBROLIZUMAB	Metastatic squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
296	PEMBROLIZUMAB	Recurrent squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
297	IFOSFAMIDE	Germ cell testicular carcinoma	Testicular cancer	Special Drugs	MIMS HK
298	METHOTREXATE	Choriocarcinoma	Trophoblastic cancer	General Drugs	MIMS HK

***There are four categories of drugs in the HA Drug Formulary:**

General Drugs	These are drugs with well-established indications and cost- effectiveness which are available for general use as indicated by patients with relevant clinical conditions and provided at standard fees and charges in public hospitals and clinics.
Special Drugs	These are drugs used under specific clinical conditions with specific specialist authorisation. Special drugs are provided at standard fees and charges in public hospitals and clinics when prescribed under specific clinical conditions. Patients who do not meet the specified clinical conditions but choose to use Special drugs are required to pay for the drugs.
Self-financed Items (SFIs) with Safety Net	These are drugs which are proven to be of significant clinical benefits but are very expensive for HA to provide as part of its standard services. These drugs are not covered by the standard fees and charges in public hospitals and clinics. Patients who require these drugs and can afford the costs have to purchase the drugs at their own expense. A safety net is provided through relevant funds to subsidize the drug expenses of patients who have financial difficulties.
SFIs without Safety Net	These include drugs with preliminary medical evidence only, drugs with marginal benefits over available alternatives but at significant higher costs, and lifestyle drugs (e.g. anti-obesity drugs). These drugs are not provided as part of HA's standard services nor covered by the standard fees and charges in public hospitals and clinics. Patients who choose to use these drugs must purchase them at their own expense.

Source: <https://www.ha.org.hk/hadf/en-us/Drug-Formulary-Management.html>